Trial Profile

A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 19 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Casirivimab/imdevimab (Primary)
Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
Sponsors Regeneron Pharmaceuticals

Most Recent Events

12 Sep 2023 Results assessing thepharmacokinetic (PK), concentration-response for na-sopharyngeal (NP) viral load (VL) reduction and immunogenicity results in pediatric outpatients presented at the 2023 American College of Clinical Pharmacology Annual Meeting
12 Sep 2023 Results presented at the 2023 American College of Clinical Pharmacology Annual Meeting
26 Jul 2022 Status changed from completed to discontinued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com